Evidence map›Paper›PMID 39622554›Full record

ArticleBMJ case reports2024

Rare case of wtTTR amyloidosis and MGUS in a patient with lung adenocarcinoma.

Ahmad Safdar, Faiz Anwer

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ahmad SafdarInternal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Faiz AnwerHematology Oncology, Cleveland Clinic, Cleveland, Ohio, USA anwerf@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis is a rare, multisystem disease that leads to deposition of misfolded proteins in various organs. This case report presents a patient with cancer with a rare diagnosis of diffuse alveolar-septal transthyretin (TTR) amyloidosis with subsequent protein electrophoresis identifying monoclonal gammopathy of unknown significance. It highlights the association of amyloidosis with malignancy and the importance of including workup for plasma cell dyscrasias in patients found to have TTR amyloidosis. There are major differences in the clinical course and treatment of amyloid light chain and amyloid transthyretin amyloidosis, and evaluation of the precursor protein(s) is critical as a guide for management.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMonoclonal Gammopathy of Undetermined SignificanceAgedAmyloid Neuropathies, FamilialHumansMaleMiddle AgedPrealbuminPrealbuminCancer interventionHaematology (incl blood transfusion)Multiple Pulmonary Nodules

Identifiers

PMID39622554
PMCPMC11624573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.